Review
Medicine, General & Internal
Francesco Condello, Carmen Spaccarotella, Sabato Sorrentino, Ciro Indolfi, Giulio G. G. Stefanini, Alberto Polimeni
Summary: The advancements in stent technologies, pharmacotherapy, and understanding of implantation techniques have reduced the risk of stent failure. However, stent thrombosis and in-stent restenosis still pose a public health problem. Various risk factors associated with patient, lesion, device, and procedure have been identified. Further research is needed to determine the time-dependence of these risk factors in the occurrence of in-stent restenosis.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Mangesh Sane, Vikas Dighe, Rucha Patil, Puthusserickal A. Hassan, Santosh Gawali, Vandana Patravale
Summary: Localized drug delivery with sustained elution characteristics from nanocarrier coated stents is a viable therapeutic approach to address concerns related to coronary stent therapy. A Sirolimus and Bivalirudin releasing nanoparticles (NPs) coated stent was fabricated for concurrent mitigation of vascular restenosis and acute stent thrombosis, showing superior anti-proliferative activity and higher cellular uptake in human coronary artery smooth muscle cells.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2021)
Article
Medicine, General & Internal
Sang Hyun Lee, Eun Kyung Lee, Hyun Joo Ahn, Sangmin M. Lee, Jie Ae Kim, Mikyung Yang, Ji Won Choi, Jeayoun Kim, Heejoon Jeong, Seungmo Kim, Jinseo Kim, Joonghyun Ahn
Summary: Current guidelines recommend delaying noncardiac surgery for 6 months after drug eluting stent implantation. However, a retrospective study found that early surgery within 6 months after coronary stent implantation did not increase the incidence of myocardial injury in patients with normal preoperative hs-cTnI. The study also showed no differences in secondary outcomes between early and late surgery groups.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Gi Suk Nam, Soyoung Kim, Yun-Suk Kwon, Min-Kyung Kim, Kyung-Soo Nam
Summary: MAP4K4 inhibitors reduce thrombus formation by regulating platelet activation, showing potential for the treatment of thrombosis.
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Fumi Yamamoto, Masahiro Natsuaki, Shoichi Kuramitsu, Masanobu Ohya, Hiromasa Otake, Kazunori Horie, Futoshi Yamanaka, Hiroki Shiomi, Gaku Nakazawa, Kenji Ando, Kazushige Kadota, Shigeru Saito, Takeshi Kimura, Koichi Node
Summary: This study assessed the association between clinical presentation at index procedure and mortality in patients with second-generation drug-eluting stent thrombosis. The results showed that the cumulative 3-year incidence of all-cause death after the index ST events was similar between patients with acute coronary syndrome (ACS) and chronic coronary syndrome (CCS), but patients in the ACS group were more likely to have early ST and higher incidences of target lesion revascularization and recurrent ST compared to the CCS group.
JACC-CARDIOVASCULAR INTERVENTIONS
(2021)
Article
Cardiac & Cardiovascular Systems
Soichiro Enomoto, Shoichi Kuramitsu, Tomohiro Shinozaki, Masanobu Ohya, Hiromasa Otake, Futoshi Yamanaka, Hiroki Shiomi, Masahiro Natsuaki, Gaku Nakazawa, Kenji Ando, Kazushige Kadota, Shigeru Saito, Toshihiro Tamura, Takeshi Kimura
Summary: This study assessed over 600 patients with DES implantation-related ST, finding no significant difference in the incidence of definite RST between first-generation and second-generation DES. Early ST and multivessel ST were identified as independent risk factors for definite RST. Definite RST significantly increased mortality risk for patients with DES thrombosis.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Article
Cardiac & Cardiovascular Systems
Masato Nakamura, Kazushige Kadota, Yoshihisa Nakagawa, Kengo Tanabe, Yoshiaki Ito, Tetsuya Amano, Yuichiro Maekawa, Akihiko Takahashi, Nobuo Shiode, Yoritaka Otsuka, Tomohiro Kawasaki, Yutaka Hikichi, Junya Shite, Ken Kozuma, Raisuke Iijima, Yoshitaka Murakami
Summary: This randomized comparison study showed that ultrathin-strut drug-eluting stents were noninferior to thin-strut drug-eluting stents in terms of target lesion failure at 1 year, indicating that differences in strut thickness among DES have little impact on clinical outcomes when implanted with intravascular imaging guidance.
JACC-CARDIOVASCULAR INTERVENTIONS
(2022)
Article
Medicine, General & Internal
Minsu Kim, Albert Youngwoo Jang, Joonpyo Lee, Jeongduk Seo, Yong Hoon Shin, Pyung Chun Oh, Soon Yong Suh, Kyounghoon Lee, Woong Chol Kang, Seung-Hwan Han
Summary: This study compared the clinical outcomes of drug-eluting balloon (DEB) angioplasty and drug-eluting stent (DES) implantation in DES in-stent restenosis (ISR) lesions. The results showed that there was no significant difference in target lesion revascularization between the DEB and DES groups during the 7-year follow-up period. However, the DEB group had better safety outcomes, with lower rates of myocardial infarction and target lesion thrombosis.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Xiang Chen, Xiaofei Gao, Jing Kan, Rajiv Shrestha, Leng Han, Shu Lu, Xuesong Qian, Bill D. Gogas, Junjie Zhang, Shao-Liang Chen
Summary: This study analyzed the incidence of definite stent thrombosis (ST) after drug-eluting stent (DES) implantation, finding that overlapping stents were associated with higher rates of definite ST and target lesion revascularization. Long-term follow-up revealed that longer overlapping stent lengths correlated with worse clinical outcomes.
CARDIOVASCULAR DRUGS AND THERAPY
(2021)
Review
Urology & Nephrology
Constance C. F. M. J. Baaten, Jonas R. Schroer, Jurgen Floege, Nikolaus Marx, Joachim Jankowski, Martin Berger, Heidi Noels
Summary: Patients with chronic kidney disease (CKD) have a higher risk of cardiovascular and thromboembolic complications, as well as hemorrhages. Altered platelet function may contribute to these complications. Further research is needed to understand the mechanisms behind these abnormalities and optimize antiplatelet treatment strategies for CKD patients.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2022)
Article
Hematology
Tomoyo Hamana, Hiromasa Otake, Shoichi Kuramitsu, Tomohiro Shinozaki, Masanobu Ohya, Kazunori Horie, Hiroyoshi Kawamoto, Futoshi Yamanaka, Masahiro Natsuaki, Hiroki Shiomi, Gaku Nakazawa, Kenji Ando, Kazushige Kadota, Shigeru Saito, Takeshi Kimura
Summary: This study found that patients with a history of cancer have a higher risk of second-generation drug-eluting stent thrombosis, particularly in late and very late stages, but not in early stages.
THROMBOSIS JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Seung-Jun Lee, Jung-Joon Cha, Young-Hoon Jeong, Sung-Jin Hong, Chul-Min Ahn, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Hyung Joon Loo, Kiyuk Chang, Yongwhi Park, Young Bin Song, Sung Gyun Ahn, Jung-Won Suh, Sang Yup Lee, Jung Rae Cho, Ae-Young Her, Hyo-Soo Kim, Moo Hyun Kim, Eun-Seok Shin, Do-Sun Lim, Byeong-Keuk Kim
Summary: The long-term prognostic implications of platelet reactivity after percutaneous coronary intervention (PCI) are important. High PRU is significantly associated with the occurrence of major adverse cardiac and cerebrovascular events (MACCE), all-cause death, and net adverse clinical events (NACE).
JACC-CARDIOVASCULAR INTERVENTIONS
(2022)
Article
Cell Biology
Xianghui Zhou, Xin Zhou, Ruirui Zhu, Zhangyin Ming, Zhipeng Cheng, Yu Hu
Summary: Our study found that oleic acid can inhibit platelet activation and reduce thrombogenesis by inhibiting the phosphorylation of multiple signaling molecules, providing new insights into the research and development of antiplatelet drugs.
CELL COMMUNICATION AND SIGNALING
(2023)
Article
Pharmacology & Pharmacy
Yulong Li, Guang Xin, Shiyi Li, Yuman Dong, Yuda Zhu, Xiuxian Yu, Chengyu Wan, Fan Li, Zeliang Wei, Yilan Wang, Kun Zhang, Qingqiu Chen, Hai Niu, Wen Huang
Summary: This study reveals the regulatory role of PD-L1 in platelet activation and thrombosis. PD-L1 knockout inhibits platelet activation and thrombus formation, and improves the severity of ischemic stroke and survival rate.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Cardiac & Cardiovascular Systems
Peter Kulyassa, Marie Anne Engh, Peter Vamosi, Peter Fehervari, Peter Hegyi, Bela Merkely, Istvan Ferenc Edes
Summary: Drug-coated balloon (DCB) therapy shows promising results in reducing the need for recurrent revascularization in drug-eluting stent in-stent restenosis (DES-ISR). In this meta-analysis, the occurrence of major cardiac adverse events (MACE) and target lesion revascularization (TLR) after DCB treatment was assessed. The results support the effectiveness of DCB treatment in early or late DES-ISR.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
